Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.

Inclusion Criteria:

• Caucasian men
• Body mass index between 20-27 kg/m^2
• T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c<69 mmol/l (<8,5%)
• T1D duration between 2-20 years
• Stimulated C-peptide ≤ 100 pmol/mL)
• Treatment with a stable basal bolus or insulin pump regimen ≥ 3 months
• Informed consent

Exclusion Criteria:

• Anemia (hemoglobin below normal range)
• Liver disease (ALAT and/or ASAT >2 times normal values) or history of hepatobiliary disorder
• Nephropathy (serum creatinine above normal range and/or albuminuria)
• Allergy or intolerance to ingredients included in the standardized meals
• Prior myocardial infarction or other cardiac events
• Any physical or psychological condition that the investigator fells would interfere with trial participation
• Treatment with any glucose-lowering drugs beside insulin